Lack of association of statin use with vitamin D levels in a hospital based population of type 2 diabetes mellitus patients

Khalida Iqbal
Aga Khan University

Najmul Islam
Agha Khan University, najmul.islam@aku.edu

Iqbal Azam Syed
Aga Khan University, iqbal.azam@aku.edu

Naseema Mehboobali
Aga Khan University, naseema.mehboobali@aku.edu

Mohammad Perwaiz Iqbal
Aga Khan University, perwaiz.iqbal@aku.edu

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_bbs

Part of the Biochemistry Commons, and the Endocrinology, Diabetes, and Metabolism Commons

Recommended Citation
Iqbal, K., Islam, N., Syed, I. A., Mehboobali, N., Iqbal, M. P. (2018). Lack of association of statin use with vitamin D levels in a hospital based population of type 2 diabetes mellitus patients. Pakistan Journal of Medical Sciences, 34(1), 204-208.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_bbs/347
INTRODUCTION

Statins are a group of cholesterol lowering drugs which inhibit HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis. They have a well-established role in decreasing serum concentration of low density lipoprotein (LDL) cholesterol, thereby reducing the risk of atherosclerotic cardiovascular disease (CVD).¹ A Cochrane review in 2013 has indicated a role of statins in the primary prevention of CVD in people with no history of this disease.² An association between CVD risk and vitamin D deficiency has also been reported in a number of studies.³,⁴ The deficiency of vitamin D is a global health problem and its prevalence is very high in South
Asian populations including Pakistan.\(^5,6\) A few studies have shown that statins significantly increase serum levels of vitamin D metabolite, 25-hydroxyvitamin D (25(OH)D).\(^7,8\) However, a recent systematic review and meta-analysis of 7 studies including 5 randomized clinical trials showed no significant effect of statin treatment on plasma levels of vitamin D.\(^9\) It has even been suggested that statin therapy may impair vitamin D status, thereby leading to increased risk of CVD.\(^10,11\) More recently, a meta-analysis on the effect of statins on vitamin D levels was inconclusive and reported “conflicting directions of effects from interventional and observation studies”.\(^12\)

Since no studies have been carried out on South Asian population on the relationship of statin use and vitamin D status, we embarked on investigating this relationship in Pakistani diabetic patients who are often put on statins to reduce CVD risk while managing the blood glucose levels. Therefore, the objective of this study was to find out if there is any association between statin use and vitamin D levels in a hospital based population of Pakistani patients with type 2 diabetes mellitus (DM).

**METHODS**

In a cross-sectional survey for the assessment of the role of statins on vitamin D levels in type 2 DM patients, 312 consecutive patients (age 22-70 years; 219 males and 93 females) were recruited from the Endocrinology Clinics of the Aga Khan University Hospital (AKUH) with informed consent. These patients had confirmed diagnosis of type 2 DM based on clinical history and fasting serum glucose ≥ 126 mg/dl as per guidelines of the International Diabetes Federation. According to the inclusion criteria, they had not been taking vitamin D supplements for the last 6 months and were not suffering from any of the chronic diseases such as tuberculosis, liver disease, uremia or cancer and were not pregnant. Majority of the recruited patients (65%) were newly diagnosed diabetes patients with duration of diabetes less than 6 months. Seventeen percent of patients had duration of the disease for more than 60 months. All the patients were on oral hypoglycemic drugs. Those on statins had been on daily dosages 5 mg (13%), 10 mg (55%) and 20 mg (32%). The study had been approved by the Ethics Review Committee of the Aga Khan University.

A brief questionnaire was used for demographic information and to find out whether they were using statins or not. Ten ml fasting (at least 4 hours) blood was collected and serum/plasma was analyzed for 25(OH) vitamin D [25(OH)D], cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, phosphate and calcium using kit

| Variable                  | Statin nonusers (n=160) | Mean±SD | Statin users (n=152) | Mean±SD | P*  |
|---------------------------|-------------------------|---------|----------------------|---------|-----|
| Gender                    |                         |         |                      |         |     |
| Males (n=219)             | 108(67.5)               | -       | 111(73)              | -       | 0.29|
| Females (n=93)            | 52(32.5)                | -       | 41(27)               | -       |     |
| Smoker (current)          |                         |         |                      |         |     |
| No                        | 128(80)                 | -       | 122(80.3)            | -       | 0.95|
| Yes                       | 32(20)                  | -       | 30(19.7)             | -       |     |
| Duration of DM (months)   | -                       | 35.8±46.8 | 63.9±70.3            | <0.01   |
| Age (yr)                  | -                       | 45.6±10.5 | 50.8±8.7             | <0.01   |
| BMI (kg/m\(^2\))         | -                       | 29.8±5.5  | 29.9±5.2             | 0.22    |
| Serum cholesterol (mg/dl) | -                       | 162±248  | 127±46               | <0.01   |
| Triglyceride (mg/dl)      | -                       | 160±86   | 144±72               | 0.08    |
| HDL-cholesterol (mg/dl)   | -                       | 25.03±7.80 | 29.29±8.91          | <0.01   |
| LDL-cholesterol (mg/dl)   | -                       | 90±36    | 63±39                | <0.01   |
| Phosphate (mg/dl)         | -                       | 3.6±0.70 | 3.75±0.74            | 0.27    |
| Calcium (mg/dl)           | -                       | 9.93±1.8 | 9.71±1.93            | 0.30    |
| 25(OH)D (ng/ml)           | -                       | 18.62±11.63 | 20.3±11.6            | 0.23    |

\(^*P\) was obtained by comparing mean values of two groups (statin users and non-users) using Independent samples t test, while percentages in the two groups (statin users and non-users) were compared using chi square.
For quality assurance, standard controls with high and low concentrations of biomarkers were run along with the test samples.

**Statistical analysis:** Statistical analyses were carried out using Statistical Package for Social Sciences® (SPSS) software version 19 for Windows® (Apache Software Foundation, USA). Mean values of continuous variables such as age, BMI, serum levels of cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, phosphate, calcium, 25(OH)D, duration of diabetes and duration of statin use were expressed as mean±SD, while categorical variables such as gender and smoking status were expressed as n(%). Mean values of variables in two groups (statin users and statin non-users) were compared using Independent sample t test. Multiple linear regression was used to observe the relationship between vitamin D levels and statin use, which was also adjusted for demographic and health related covariates.

**RESULTS**

As shown in Table I, mean age and duration of diabetes in the statin non-users group were significantly lower compared to the statin users group ($P < 0.01$). Similarly, mean concentrations of serum cholesterol and LDL cholesterol were significantly lower in the statin users group compared to the non-users group ($P < 0.01$). However, HDL-cholesterol levels were significantly higher in the statin users group ($P < 0.01$). No significant difference was found when the mean values of 25(OH)D between statin-users and statin non-users were compared using Independent sample t test ($P = 0.23$). No significant differences with respect to other variables were found between the two groups.

Regarding mean duration of statin use and dosages of statins, out of 152 statin users, the data of 118 were available for regression analysis. Mean duration of statin treatment among the statin users group was 17.99±21.42 months, while the mean dosage of statins in this group was 12.7±5.3 mg.

The effect of different factors, particularly duration of statin use is shown in Table II. Gender, age, BMI, duration of DM, levels of serum cholesterol, HDL-cholesterol and calcium were found to be significant at the univariate level.

### Table-II: Effect of statin use on the serum levels of vitamin D using multiple linear regression.

| Variable                     | Crude $\beta$[SE(\(\beta\))] | $P$  | Adjusted* $\beta$[SE(\(\beta\))] | $P$  |
|------------------------------|---------------------------------|------|-----------------------------------|------|
| Statin use duration (months) | 0.07(0.039)                     | 0.076| 0.012(0.042)                      | 0.768|
| Age (yr)                     | 0.227(0.067)                    | 0.001| 0.117(0.071)                      | 0.099|
| Gender                       |                                 |      |                                   |      |
| Male (Ref.)***               |                                |      |                                   |      |
| Female                       | 3.176(1.47)                    | 0.031| 3.496(1.47)                       | 0.018|
| BMI (kg/m²)                  | -0.338(0.133)                  | 0.005| -0.294(0.132)                     | 0.027|
| Type 2 DM duration (months)  | 0.041(0.011)                   | <0.001| 0.035(0.013)                      | 0.006|
| Current Smoking              |                                 | 0.388 |                                   | 0.582|
| No (Ref.)***                 |                                |      |                                   |      |
| Yes                          | -1.495(1.728)                  | -    | 0.974(1.765)                      | -    |
| Cholesterol (mg/dl)          | -0.28(0.014)                   | 0.043| -0.057(0.019)                     | 0.003|
| LDL-C (mg/dl)                | -0.011(0.017)                  | 0.500| 0.062(0.024)                      | 0.01 |
| HDL-C (mg/dl)                | 0.16(0.076)                    | 0.035| -                                 | -    |
| Triglyceride (mg/dl)         | 0.006(0.008)                   | 0.468| -                                 | -    |
| Phosphate (mg/dl)            | -0.455(0.913)                  | 0.618| -                                 | -    |
| Calcium (mg/dl)              | -0.714(0.353)                  | 0.044| -                                 | -    |
| Constant                     | -                               | -    | 22.915(5.740)                     | <0.001|

*Model was adjusted for age, gender, BMI, duration of type 2 diabetes mellitus, current smoking, serum cholesterol and LDL-cholesterol with coefficient of determination ($R^2$)= 0.135.

** $\beta$[SE(\(\beta\))] refers to regression co-efficient with its standard error.

***Ref. indicates the reference group category in regression.
At multivariable level, when the relationship between duration of statin use and serum level of vitamin D was adjusted for other factors, which were either biologically important or significant at the univariate level, the variables like gender, BMI, duration of type 2 diabetes, serum levels of cholesterol and LDL-cholesterol were found to be significantly associated.

Current smoking was kept in the model because of its biological importance. Regarding the duration of statin use, one month increase in statin use was found to be responsible for an average increase in vitamin D level by 0.012 ng/ml when adjusted for age, gender, BMI, duration of type 2 DM, current smoking, serum cholesterol and LDL-cholesterol. The value of coefficient of determinations ($R^2$) of 0.135 indicates that 13.5% variation in serum level of vitamin D is explained by the investigated covariates.

**DISCUSSION**

There are numerous reports about high prevalence of hypovitaminosis D in South Asian general population as well as patients with type 2 DM. Since diabetic patients have an additional risk of developing CVD, they are often prescribed statins to control their LDL cholesterol along with usual management of their serum glucose level. However, long-term use of statins may produce hepatotoxicity. Since cholesterol metabolism and vitamin D both share a common metabolic pathway, it is possible that prolonged use of statins would not only inhibit cholesterol biosynthesis but also reduce levels of 7-dehydrocholesterol, a precursor molecule for vitamin D3, thereby leading to low concentration of vitamin D in the body. This would render such patients vulnerable to risks associated with vitamin D deficiency. However, in the present study we found no difference in serum levels of vitamin D in statin users and non-users in type 2 DM patients. Similar findings have been reported by Ertugrul et al, who have shown no significant effect of pravastatin and fluvastatin on serum levels of 25(OH)D.

In a randomized controlled trial on healthy postmenopausal women, simvastatin was found to have no effect on vitamin D status even after 52 weeks of treatment. Similar results have been found by Mazidi et al on an Iranian population of patients with dyslipidemia. On the contrary, Sathyapalan et al have reported increased concentration of 25(OH)D following therapy with atorvastatin in type 2 DM patients in UK. Similarly, 4 studies (two carried out in Turkey, one in Spain and another one in Germany) have also shown increased serum levels of 25(OH)D following treatment with rosvastatin and atorvastatin. Most of these studies reporting increased levels of 25(OH)D following statin treatment had small sample sizes which could lead to overestimation of therapy effect, and therefore, it was difficult to derive any substantive conclusion. Perhaps, this could be the reason that most recent studies on this pleiotropic effect of statins have failed to show any significant increase in vitamin D levels. A recent meta-analysis of data from seven studies failed to show any significant effect of statins treatment on plasma concentrations of vitamin D. All these reports lend support to our current results indicating lack of association between statin use and serum levels of vitamin D in type 2 DM patients. The multiple linear regression model to investigate this relationship while adjusting for other related factors mentioned above is a strength of this study.

Our results must be seen in the context of certain limitations. Our collection of blood samples was across the whole year and the samples could not be divided into those collected during winter, spring or summer. Furthermore, no dietary information was obtained. However, in spite of these limitations, we have been able to report lack of association between statin use and vitamin D levels in a hospital-based population of type 2 DM patients using a reasonably large sample size.

In order to obtain conclusive evidence regarding the relationship of statin use with vitamin D status in South Asian population, prospective, randomized, placebo controlled and double blinded multicentric clinical trials with large sample size would be required.

**CONCLUSION**

There is no association between statin use and levels of vitamin D in a hospital-based Pakistani population of type 2 DM patients.

**ACKNOWLEDGEMENTS**

The study had been supported by a Grant No. PSF/Res/AKU-Med(336) to MPI by the Pakistan Science Foundation and the Biological and Biomedical Sciences (BBS) Departmental Research Funds of the Aga Khan University. We acknowledge the technical assistance of Dr. Ali Asghar. Khalida Iqbal carried out this study as part of her PhD thesis at the University of Karachi.

**Sources of Funding:** Pakistan Science Foundation and BBS Department, Aga Khan University.
Conflict of Interest: The authors declare that there are no conflicts of interest.

REFERENCES

1. Ray KK, Kastelein JJ, Boekholdt SM, Nicholls SJ, Khaw KT, Ballantyne CM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidemias 2011. Eur Heart J. 2014;35:960-968. doi:10.1093/eurheartj/ehu107.

2. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. 2013;Rev:1:CD004816. doi:10.1002/14651858.CD004816.pub5.

3. Zittermann A, Gummert JF, Borgermann JH. The role of vitamin D in dyslipidemia and cardiovascular disease. Curr Pharm Des. 2011;17:933-942.

4. Weiland PG, Grant WB, Howie-Equivel J. Does sufficient evidence exist to support a causal association between vitamin D status and cardiovascular disease risk? An assessment using Hill’s criteria for causality. Nutrients. 2014;6(6):3403-3430. doi:10.3390/nu6050340.

5. Akhtar S. Vitamin D status of South Asian populations – risks and opportunities. Crit Rev Food Sci Nutr. 2016;56(11):1925-1940. doi:10.1080/10408398.2013.807419

6. Mehbboobali N, Iqbal SP, Iqbal MP. High prevalence of vitamin D deficiency and insufficiency in a low income peri-urban community in Karachi. J Pak Med Assoc. 2015;65:946-949.

7. Ernst JB, Kuhn J, Becker T, Dreier J, Börgermann J, Knabbe KI and NM. Association between circulating 25-hydroxyvitamin D levels and medication use in patients scheduled for cardiac surgery. Nutr Metab Cardiovasc Dis. 2015;25:280-286. doi:10.1016/j.numecd.2014.10.014.

8. Pérez-Castrillón JL., Vega G, Abad L, Sanz A, Chaves J, Hernandez G, et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol. 2007;99(7):903-5.

9. Sahebkar A, Reiner Z, Simental-Mendia LE, Ferretti G, Corte CD, Nobili V. Impact of statin therapy on plasma vitamin D levels: A systematic review and meta-analysis. Curr Pharm Des. 2017;23(6):861-869. doi:10.1074/1381612822666161086150542.

10. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281.

11. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168(11):1174-1180. doi:10.1001/archinte168.11.1174.

12. Mazidi M, Rezaie P, Vatanparast H, Kengne AP. Effects of statins on serum vitamin D concentrations: a systematic review and meta-analysis. Eur J Clin Invest. 2017;47(1):93-101. doi:10.1111/eci.12698.

13. Khan AH, Iqbal R, Naureen G, Dar FJ, Ahmed, FN. Prevalence of vitamin D deficiency and its correlates: results of a community-based study conducted in Karachi, Pakistan. Arch Osteoporos. 2012;7:275-282.

14. Laway BA, Kotwal SK, Shah ZA. Pattern of 25 hydroxy vitamin D status in North Indian people with newly detected type 2 diabetes: A prospective case control study. Indian J Endocrin Metab. 2014;18(8):726-730. doi: 10.4103/2230-8210.139242.

15. Sheth JJ, Shah A, Sheth FJ, Trivedi S, Lele M, Shah N et al. Does vitamin D play a significant role in type 2 diabetes? BMC Endocr Disord. 2015;15;5. doi: 10.1186/s12902-015-0033-8.

16. Mazhar F. Possible effect of statins on serum vitamin D levels in patients with chronic renal disease. Saudi J Kidney Dis Transpl. 2017;28(2):428-429.

17. Ertugrul DT, Yavuz B, Cil H, Ata N, Akin KO, Kucukazman M, et al. STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D. Cardiovasc Ther. 2011;29:146-152. doi: 10.1111/j.1755-5922.2010.00411.x.

18. Rejmark L, Vestergaard P, Heickendorf L, Mosekilde L. Simvastatin does not affect vitamin D status, but low vitamin D levels are associated with dyslipidaemia: results from a randomized controlled trial. Int J Endocrinol. 2010;957174. doi:10.1155/2010/957174.

19. Mazidi M, Rokni H, Sahebkar AH, Mohammedi A, Ghayour Mobarhan M, Ferns GA. Simvastatin treatment does not affect serum vitamin D concentrations in patients with dyslipidaemia: A randomized double-blind placebo-controlled cross-over trial. Int J Prev Med. 2016;7:80. doi: 10.4103/2008-7802.183652.

20. Sathyapalan T, Shepherd J, Atkin SL, Kilpatrick ES. The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study. Diabetes Obes Metab. 2013;15(8):767-769. doi:10.1111/dom.12074.

21. Yavuz B, Ertugrul DT, Cil H, Ata N, Akin KO, Yalcin AA, et al. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther. 2009;23:295-299. doi:10.1007/s10557-009-6181-8.

22. Ott C, Raff U, Schneider MP, Titze SI, Schmieder RE. 25-hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin. Clin Res Cardiol. 2013;102(4):299-304. doi:10.1007/s00392-012-0534-1.

23. Anagnostis P, Adamidou F, Slavakis A, Polyzos SA, Selalmatzidou D, Panagiotou A, et al. Comparative effect of atorvastatin and simvastatin on 25-hydroxy-vitamin D levels in non-diabetic patients with dyslipidaemia: A randomized controlled open-label pilot study. Open Cardiovasc Med J. 2014;8:55-60. doi:10.2174/1874192401408010055.

Authors’ Contributions:

NI and MPI conceived and designed the experiments.
Kl and NM performed the experiments.
IA, KI, NI, and MPI analyzed and interpreted the data.
KI, MPI, and NM contributed reagents, materials and analysis tools.
MPI, NI and IA prepared the final manuscript.